enVVeno Medical reports FY24 EPS ($1.27) vs. ($1.91) last year

“Throughout 2024, we executed on our primary objectives – the successful submission of our PMA application for the VenoValve, and the advancement of enVVe towards its U.S. pivotal trial, both critical milestones for enVVeno Medical (NVNO),” commented Robert Berman, CEO of enVVeno Medical. “We also added two key members to our Executive team in order to begin preparations for the commercialization of the VenoValve and will continue to add to our team following a positive decision from the FDA. We are on the precipice of achieving what no other company has been able to achieve, a viable solution for the millions of patients that suffer from severe deep venous Chronic Venous Insufficiency.”